Woodline Partners LP Has $22.34 Million Holdings in ICU Medical, Inc. $ICUI

Key Points

• Woodline Partners LP increased its holdings in ICU Medical by 31.6%, now owning approximately 0.65% of the company, valued at $22.34 million.
• ICU Medical recently reported $2.10 EPS for the quarter, exceeding expectations of $1.44, despite a year-over-year revenue decline of 8%.
• Research firms have upgraded ICU Medical's stock ratings, with Wall Street Zen upgrading to a "buy" rating and Piper Sandler setting a price target of $145.00.

Woodline Partners LP lifted its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 31.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,910 shares of the medical instruments supplier's stock after acquiring an additional 38,671 shares during the quarter. Woodline Partners LP owned approximately 0.65% of ICU Medical worth $22,344,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ICUI. Deutsche Bank AG boosted its holdings in shares of ICU Medical by 41.1% in the 4th quarter. Deutsche Bank AG now owns 21,792 shares of the medical instruments supplier's stock worth $3,381,000 after acquiring an additional 6,345 shares in the last quarter. Gotham Asset Management LLC boosted its holdings in shares of ICU Medical by 22.3% in the 4th quarter. Gotham Asset Management LLC now owns 40,610 shares of the medical instruments supplier's stock worth $6,301,000 after acquiring an additional 7,410 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of ICU Medical by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,204 shares of the medical instruments supplier's stock worth $1,894,000 after acquiring an additional 478 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of ICU Medical in the 4th quarter worth approximately $911,000. Finally, Quantedge Capital Pte Ltd acquired a new position in shares of ICU Medical in the 4th quarter worth approximately $2,529,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $130.57 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26. The firm has a fifty day moving average of $126.39 and a two-hundred day moving average of $134.20. The stock has a market capitalization of $3.22 billion, a price-to-earnings ratio of -85.90 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. During the same quarter in the prior year, the company earned $1.56 EPS. The firm's quarterly revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Insiders Place Their Bets

In other news, Director David C. Greenberg acquired 1,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was acquired at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the transaction, the director directly owned 7,960 shares in the company, valued at approximately $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on ICUI. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Piper Sandler started coverage on shares of ICU Medical in a research report on Friday, August 15th. They issued an "overweight" rating and a $145.00 price objective for the company. Finally, Raymond James Financial dropped their target price on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $179.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.